|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Eplerenone#Contraindications]] |
| {{Eplerenone}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Contraindications==
| |
| | |
| ===For All Patients===
| |
| | |
| INSPRA is contraindicated in all patients with:
| |
| | |
| serum potassium >5.5 mEq/L at initiation,
| |
| creatinine clearance ≤30 mL/min, or
| |
| concomitant administration of strong CYP3A4 inhibitors (e.g., [[ketoconazole]], [[itraconazole]], [[nefazodone]], [[troleandomycin]], [[clarithromycin]], [[ritonavir]], and [[nelfinavir]]). [SeeDRUG INTERACTIONS (7.1), CLINICAL PHARMACOLOGY (12.3).]
| |
| | |
| ===For Patients Treated for Hypertension===
| |
| | |
| INSPRA is contraindicated for the treatment of [[hypertension]] in patients with:
| |
| | |
| type 2 diabetes with microalbuminuria,
| |
| serum creatinine >2.0 mg/dL in males or >1.8 mg/dL in females,
| |
| creatinine clearance <50 mL/min, or
| |
| concomitant administration of potassium supplements or potassium-sparing diuretics (e.g., [[amiloride]], [[spironolactone]], or [[triamterene]]). [See WARNINGS AND PRECAUTIONS (5.1), ADVERSE REACTIONS (6.2), DRUG INTERACTIONS (7), and CLINICAL PHARMACOLOGY (12.3).]<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = INSPRA (EPLERENONE) TABLET, FILM COATED [G.D. SEARLE LLC DIVISION OF PFIZER INC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a55a39ff-1bd5-428b-a64f-c44262e2f3ed | publisher = | date = | accessdate = 28 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| [[Category:Aldosterone antagonists]]
| |
| [[Category:Pfizer]]
| |
| [[Category:Lactones]]
| |
| [[Category:Epoxides]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |